T Cell Assays
Charles River’s translatable immuno-oncology platform enables oncology researchers to rapidly assess the T-cell-modulated immune function of therapeutic modalities in high-throughput and high-content imaging platforms illustrating T cell activation, increased T cell proliferation, T cell exhaustion, T cell chemotaxis, and cytokine response. Observe T-cell-mediated cytotoxicity in both 2D and 3D platforms. Start your biologic or small molecule on the road to discovery with our optimized T cell assays. Select T cell assays are available in an off-the-shelf format yielding results 3-5 weeks from receipt of compounds.
- Cytokine Response Assays
- T Cell-Mediated Proliferation CTG Assay
- T Cell-Mediated Exhaustion Assay
- T Cell-Mediated Chemotaxis Assay
- T Cell-Mediated Cytotoxicity Assay
- 3D Spheroid T Cell-Mediated Cytotoxicity Assay
These simple and multicellular T cell assays are validated with standard of care molecules, including checkpoint inhibitors and a selection of small-molecule inhibitors of targets known to modulate immune responses, confirming Charles River’s predictive immuno-oncology platform. This comprehensive panel of T cell assays addresses every step of the cancer-immunity cycle.
A Translational Platform for Immuno-Oncology Drug Discovery
Charles River has developed a platform to profile your new agent in in vitro immuno-oncology assays that mimic this complex biology. Our platform is focused on improving translational relevance to support the progression of your compound into in vivo PD studies, confirming immune cell activation, immune cell population changes in the tumor, and cell surface marker changes of immune activation. Your compound can be translated into our in vivo models, including fully validated syngeneic models or humanized mouse models engrafted with human PBMC or CD34+ cells inoculated with tumors from our PDX collection.
T cell assays are used to generate information on compounds from each stage of the drug discovery process to inform and progress therapies rapidly from in vitro assays to in vivo studies and, ultimately, successfully to the clinic.
Interview with our Lead Oncology Scientist: Developing a Translational Immuno-Oncology Platform